Efficacy and Safety of177Lu-FAP-2286 Targeted Radionuclide Therapy in Patients with Locoregionally Advanced or Metastatic Pancreatic Cancer (EANM 2026) - Sep 29, 2026 - Abstract #EP-0996; "177Lu-FAP-2286 provides a promising, low-toxicity salvage option for refractory pancreatic cancer. Its core clinical value lies in potent symptom palliation and functional recovery, which translate into significant survival benefits, suggesting that functional response may be a more sensitive indicator than traditional radiological criteria in this stroma-dense malignancy."
Clinical • Metastases • Oncology • Pancreatic Cancer • Solid Tumor
|
|
T. Xu; C. Tian; H. Yang; Y. Chen
|